

ACHN (ATCC® CRL-1611™)

Organism: Homo sapiens, human / Tissue: kidney; derived from metastatic site: pleural effusion / Disease: renal cell adenocarcinoma

GENERAL INFORMATION	CHARACTERISTICS	CULTURE METHOD	SPECIFICATIONS	HISTORY	DOCUMENTATION	SHARE	EMAIL	PRINT
Permits and Restrictions		<input type="button" value="View Permits"/>						
Organism	Homo sapiens, human							
Tissue	kidney; derived from metastatic site: pleural effusion							
Product Format	frozen							
Morphology	epithelial							
Culture Properties	adherent							
Biosafety Level	1							
	<i>Biosafety classification is based on <u>U.S. Public Health Service Guidelines</u>, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.</i>							
Disease	renal cell adenocarcinoma							
Age	22 years							
Gender	male							
Ethnicity	Caucasian							
Applications	ACHN may be of use for antiproliferative studies using human interferons or interferon inducers.							
Storage Conditions	liquid nitrogen vapor temperature							

ACHN (ATCC® CRL-1611™)

Organism: Homo sapiens, human / Tissue: kidney; derived from metastatic site: pleural effusion / Disease: renal cell adenocarcinoma

GENERAL INFORMATION	CHARACTERISTICS	CULTURE METHOD	SPECIFICATIONS	HISTORY	DOCUMENTATION	SHARE	EMAIL	PRINT
Derivation	The ACHN cell line was initiated in November, 1979 from the malignant pleural effusion of a 22-year-old Caucasian male with widely metastatic renal adenocarcinoma (autopsy confirmed). Cells were seeded directly to culture flasks in Eagle's MEM with 10% FBS, then maintained and passaged 150 days in flasks. Cells were then inoculated subcutaneously into nude mice. After 4 weeks, palpable, locally invasive tumors were noted. Both the original cells (ACHN) and those recovered from nude mouse tumors were growth-inhibited by human Interferons.							
Clinical Data	22 years Caucasian male							
Tumorigenic	Yes							
Effects	Yes, in nude mice (Tumors developed within 21 days at 100% frequency (5/5) in nude mice inoculated subcutaneously with 10(7) cells)							
Comments	Growth is inhibited by human interferon [Hogan, T. F., personal communication].							

ACHN (ATCC® CRL-1611™)

Organism: Homo sapiens, human / Tissue: kidney; derived from metastatic site: pleural effusion / Disease: renal cell adenocarcinoma

GENERAL INFORMATION	CHARACTERISTICS	CULTURE METHOD	SPECIFICATIONS	HISTORY	DOCUMENTATION	SHARE	EMAIL	PRINT
Complete Growth Medium	The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.							
Subculturing	<p>Volumes are given for a 75 cm² flask. Increase or decrease the amount of dissociation medium needed proportionally for culture vessels of other sizes.</p> <ol style="list-style-type: none"> 1. Remove and discard culture medium. 2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin - 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor. 3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes). Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal. 4. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting. 5. Add appropriate aliquots of the cell suspension to new culture vessels. 6. Incubate cultures at 37°C. <p>Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:3 is recommended Medium Renewal: 2 to 3 times per week</p>							
Cryopreservation	<p>Freeze medium: Complete growth medium, 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor temperature</p>							
Culture Conditions	<p>Atmosphere: air, 95%; carbon dioxide (CO₂), 5% Temperature: 37°C</p>							

ACHN (ATCC® CRL-1611™)

Organism: Homo sapiens, human / Tissue: kidney; derived from metastatic site: pleural effusion / Disease: renal cell adenocarcinoma

GENERAL INFORMATION	CHARACTERISTICS	CULTURE METHOD	SPECIFICATIONS	HISTORY	DOCUMENTATION	SHARE	EMAIL	PRINT
	STR Profile		Amelogenin: X CSF1PO: 11 D13S317: 12 D16S539: 12,13 D5S818: 12 D7S820: 9,11 THO1: 8 TPOX: 8,11 vWA: 16,17					
	Isoenzymes		G6PD, B					

ACHN (ATCC® CRL-1611™)

Organism: Homo sapiens, human / Tissue: kidney; derived from metastatic site: pleural effusion / Disease: renal cell adenocarcinoma

GENERAL INFORMATION	CHARACTERISTICS	CULTURE METHOD	SPECIFICATIONS	HISTORY	DOCUMENTATION	SHARE	EMAIL	PRINT
Name of Depositor	TF Hogan							
Deposited As	<i>Homo sapiens</i>							
Year of Origin	November, 1979							
References	<p>Tumors developed within 21 days at 100% frequency (5/5) in nude mice inoculated subcutaneously with 10(7) cells</p> <p>The ACHN cell line was initiated in November, 1979 from the malignant pleural effusion of a 22-year-old Caucasian male with widely metastatic renal adenocarcinoma (autopsy confirmed). Cells were seeded directly to culture flasks in Eagle's MEM with 10% FBS, then maintained and passaged 150 days in flasks. Cells were then inoculated subcutaneously into nude mice. After 4 weeks, palpable, locally invasive tumors were noted. Both the original cells (ACHN) and those recovered from nude mouse tumors were growth-inhibited by human interferons.</p> <p>Kochevar J. Blockage of autonomous growth of ACHN cells by anti-renal cell carcinoma monoclonal antibody 5F4. Cancer Res. 20: 2968-2972, 1990. PubMed: 2334900</p>							

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.